Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

CD73 (ecto-5′-nucleotidase) has recently been established as a promising immuno-oncology target. Given its role in activating purinergic signaling pathways to elicit immune suppression, antagonizing CD73 (i.e., releasing the brake) offers a complimentary pathway to inducing anti-tumor immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Geoghegan, James C., Diedrich, Gundo, Lu, Xiaojun, Rosenthal, Kim, Sachsenmeier, Kris F., Wu, Herren, Dall'Acqua, William F., Damschroder, Melissa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037986/
https://www.ncbi.nlm.nih.gov/pubmed/26854859
http://dx.doi.org/10.1080/19420862.2016.1143182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037986/
https://www.ncbi.nlm.nih.gov/pubmed/26854859
http://dx.doi.org/10.1080/19420862.2016.1143182

Ejemplares similares